Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection.
about
Amaranth oil application for coronary heart disease and hypertensionNeutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infectionHLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressorsHIV-1 neutralizing antibodies: understanding nature's pathwaysThe Antibody Response against HIV-1Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogeniesA directed molecular evolution approach to improved immunogenicity of the HIV-1 envelope glycoproteinHuman immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodiesAntibody-Mediated Fcγ Receptor-Based Mechanisms of HIV Inhibition: Recent Findings and New Vaccination StrategiesCorrelation of acute humoral response with brain virus burden and survival time in pig-tailed macaques infected with the neurovirulent simian immunodeficiency virus SIVsmmFGbInternational network for comparison of HIV neutralization assays: the NeutNet report.Effect of trimerization motifs on quaternary structure, antigenicity, and immunogenicity of a noncleavable HIV-1 gp140 envelope glycoprotein.A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolatesApplying bioinformatics for antibody epitope prediction using affinity-selected mimotopes - relevance for vaccine designEvidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usageViral genetic evolution in macaques infected with molecularly cloned simian immunodeficiency virus correlates with the extent of persistent viremia.Neutralizing antibodies in sera from macaques infected with chimeric simian-human immunodeficiency virus containing the envelope glycoproteins of either a laboratory-adapted variant or a primary isolate of human immunodeficiency virus type 1.Characterization of simian-human immunodeficiency virus envelope glycoprotein epitopes recognized by neutralizing antibodies from infected monkeysStudy of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokinesResistance to replication of human immunodeficiency virus challenge in SCID-Hu mice engrafted with peripheral blood mononuclear cells of nonprogressors is mediated by CD8(+) T cells and associated with a proliferative response to p24 antigen.Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques.Short- and long-term clinical outcomes in rhesus monkeys inoculated with a highly pathogenic chimeric simian/human immunodeficiency virus.Increased neutralization sensitivity and reduced replicative capacity of human immunodeficiency virus type 1 after short-term in vivo or in vitro passage through chimpanzees.Identification of gp120 regions targeted by a highly potent neutralizing antiserum elicited in a chimpanzee inoculated with a primary human immunodeficiency virus type 1 isolateDeterminants of neutralization resistance in the envelope glycoproteins of a simian-human immunodeficiency virus passaged in vivo.Characterization of primary isolate-like variants of simian-human immunodeficiency virusLymphocyte activation during acute simian/human immunodeficiency virus SHIV(89.6PD) infection in macaques.Detection of antibody-dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type 1 infection.Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques.Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors.Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells.Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection.Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects.Human immunodeficiency virus type 1 variants isolated from single plasma samples display a wide spectrum of neutralization sensitivityCytokines, plasma immune activation markers, and clinically relevant surrogate markers in human immunodeficiency virus infectionPathogenicity and immunogenicity of attenuated, nef-deleted HIV-1 strains in vivo.B cell depletion in HIV-1 subtype A infected Ugandan adults: relationship to CD4 T cell count, viral load and humoral immune responses.Comparing HIV-1 and HIV-2 infection: Lessons for viral immunopathogenesis.
P2860
Q21245685-382795E9-212A-4FA1-AFB4-5B532ED7E5A0Q24538985-4A5E339D-94B9-4848-8DCF-76616D141BD7Q24676982-B035AEC8-D1B9-4E36-B2F9-5D5A31A6FC0EQ27000480-318D8013-89FF-4748-A5B7-7378A2214D77Q27000889-900A51A6-5AB9-40D2-BC90-594C2B395463Q28602877-4E2C3F71-F533-4966-9BF5-3203257A86A1Q28743092-1452186F-2387-49DA-8E4A-6ABA9DB7F6FAQ29619015-5389D233-BF4E-40CE-9C12-CF5B357A09AAQ30408097-B41819E1-EADC-4722-944D-C7D657452830Q30478136-96365B5D-E7D4-425E-B944-548F590F3DD0Q33410826-4ED631CA-7EA8-4F7E-97F1-A7852D9BAA72Q33571825-02D9C1FE-2638-4A36-83AF-6566782B058AQ33603494-59E77714-05A5-4F0E-B224-D3161A697BB5Q33743491-CF546050-2FE6-4390-B85C-0F3F5E969E88Q33782296-A4F58752-2B8B-4DA6-8444-71E0E3236037Q33783429-3F08BB49-286F-4075-A5C1-5797C46F9414Q33783516-3C99E99E-8173-4629-88BE-853AFFDAA24BQ33785114-3437C0B4-F6AC-44EE-A722-2D7F590FF5D2Q33786049-374E40DC-8EB4-46DE-9A19-B1715FCFEF63Q33794973-A3D1AD37-1E59-4D44-96C0-A69C41D45FC9Q33798154-743E3661-96E8-467D-ABD3-AC5182BD7AE7Q33800760-8DBA1630-8C67-4B8C-A86F-1128F9FADC9DQ33808774-BB67B462-680F-41F7-999D-AD5BFEAEAF0AQ33810203-3FB8481F-ECE5-49B8-8577-E9E822D64F99Q33811940-B4EB75FD-AD87-4CED-A196-4B5AEC90FC5EQ33821658-B9B8E44D-5ECF-48F5-A1D1-3B1490DA27D2Q33825229-58F000AB-8391-4A40-9C0E-1C2A574CA280Q33825296-FCC7A8DE-DE4C-465A-9053-416D14CA2479Q33834852-3A5DC9F5-6C3D-4C9C-887D-4DDAB6AAC6EFQ33835295-E1BC7FB8-9EE1-409F-AC44-E0E052F4657FQ33842286-C47E6768-16B0-443D-9471-916F0BB56FA4Q33843345-12B98CF1-01B3-4310-AC8A-87FA7CE27FF2Q33844334-8A5293AE-AA70-47E1-8D7C-3D04D3A5AF82Q33847697-E54045F6-1160-4DA9-A8D2-F81215F8A3D4Q33949316-F747CDD6-D073-466F-9D33-09F6852BA0BFQ33987391-E583C4B9-5D56-4A27-A446-E9DFB0BC1D6BQ33997410-85E3F27C-46B0-417A-95BF-E19CC4351B28Q34007084-CF174E3D-FAA2-46BE-9065-321E187B6E2AQ34008741-2A2C9336-2718-4172-9D80-8E5B91FA7553Q34035802-FAED4F42-7BEB-47E6-8105-20F2B73BA55A
P2860
Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh-hant
name
Neutralizing antibody response ...... term-nonprogressive infection.
@en
Neutralizing antibody response ...... term-nonprogressive infection.
@nl
type
label
Neutralizing antibody response ...... term-nonprogressive infection.
@en
Neutralizing antibody response ...... term-nonprogressive infection.
@nl
prefLabel
Neutralizing antibody response ...... term-nonprogressive infection.
@en
Neutralizing antibody response ...... term-nonprogressive infection.
@nl
P2093
P356
P1476
Neutralizing antibody response ...... term-nonprogressive infection.
@en
P2093
Bolognesi DP
Montefiori DC
Pilgrim AK
P304
P356
10.1086/516508
P407
P577
1997-10-01T00:00:00Z